Boehringer Ingelheim has launched Prevexxion RN and Prevexxion RN+HVT+IBD, the next generation of Marek’s disease vaccines, in the UK and Europe.

Prevexxion RN is composed of a serotype-1 construct vaccine which Boehringer says offers a unique balance between safety and efficacy against the most virulent types of Marek’s disease virus strains.

Prevexxion RN+HVT+IBD is a solution combining Prevexxion RN and Vaxxitek HVT+IBD in one ampoule. It is designed to meet the needs of customers in long-life bird segments with protection from the hatchery.

Prevexxion RN vaccines are available in ampoules of 1000, 2000, and 4000 doses, frozen in liquid nitrogen.

Jerôme Baudon, Head of Poultry at Boehringer Ingelheim, said: “Our Prevexxion RN range provides value through innovation to Marek sensitive poultry producers looking for continuous live production productivity improvement and effective protection. Field and lab experiments conducted worldwide demonstrated its safety, efficacy and its strong, early, and long-lasting protection through the lifespan of the birds and against very virulent Marek’s disease challenge.

Prevexxion RN is the new golden standard for Marek's disease vaccination programs2”.

For more information, contact your Boehringer Ingelheim representative.

Reference

  1. Bublot M. et al., llth Symposium on Marek's Disease and Avian Herpesviruses, 2016

Whilst you're here, take a moment to see our latest job opportunities for vets.